--- * Corresponding author. Tel.: +81-75-383-7055; fax: +81-75-383-2805; e-mail: teruyuki@scl.kyoto-u.ac.jp (T.K.) or aoyama.yasuhiro.78z@st.kyoto-u.ac.jp (Y.A.) Current MRI (Magnetic Resonance Imaging) is based on the 1 H NMR relaxation of water and affords morphological images of the body. 1 New directions of MRI focus on specific detection of tumors, which may be MR-imaged using either tumor targeters appropriately labeled with MR-responsible moieties such as 19 F nuclei 2 or paramagnetic contrast agents, 3 or specific signal amplification techniques such as hyperpolarization 4 and chemical exchange saturation transfer 5 for tumor-responsible small molecules such as pyruvate, H2O2, or glucose. Recently, we reported a different approach. 6 A phosphorylcholine polymer (PMPC) enriched with 13 C at the methyl groups with a mean molecular weight of Mn = 63,000 was found to accumulate highly selectively and efficiently in the tumor (colon 26) of tumorbearing mice primarily by the so-called EPR (Enhanced Permeability and Retention) effect, and the tumor could be clearly MR-visualized with this 13 C-concentrated polymeric nano-probe by the 1 H-13 C double-resonance 7 (heteronuclear correlation) technique. 6c This probe thus provides a novel example of a self-traceable EPR polymer that is free from foreign labeling. However, there are still some issues that need to be addressed if this probe is to have wider applicability as a tumor imager. One issue is the slowness of accumulation and clearance. Another involves the general utility of the EPR effect 8 , i.e., the size-allowed invasion and retention of nano-particles in tumor tissues which usually have a defective vascular wall with a wide opening and undeveloped lymphatic drainage. Although the EPR effect has been widely used for the passive targeting of tumors, 9 the EPR-susceptibility of tumor tissues depends on the type of tumor. 10 While colon 26, a mouse rectal cancer cell line, is highly susceptible to EPR, this is not necessarily true for other types of tumors. 11 In the present work, we prepared a conjugate of 13 C-PMPC as an MR signal generator with an antibody fragment as an active tumor targeter, and investigated the performance of this conjugate with the above issues in mind. We report here that the antibody-functionalized probe can selectively image an antibody- Methacryloyloxyethylphosphorylcholine (MPC) enriched with 13 C at the choline methyl groups was polymerized under the atom-transfer radical polymerization (ATRP) conditions 12 using furan-protected maleimide bromide (R-Br) as an initiator and CuBr/2,2'-bipyridine as a catalyst, according to the scheme n(MPC) + R-Br  R-(MPC)n-Br (Scheme 1) 6c . The polymer thus obtained ( 13 C-PMPC) had a mean molecular weight of Mn = 35,000 (n = 118) and a polydispersity index of Mw/Mn = 1.4. This was subjected to coupling with a fragment (scFv) of Herceptin, a well-known clinical antibody against antigen Her2 that is expressed in breast cancer as well as gastric cancer. 13 The actual fragment used (scFv) was a 257-amino acid sequence (from M1 to C257) that contained fragments of the heavy and light chains of Herceptin, conjugated with a nonapeptide (H6G2C) composed of a His-tag (H6) linked with a tripeptide glycine-glycine-cysteine (G2C) at the C-terminus (Supplementary Information for details). 14 The genetically engineered single-chain fragment variable (scFv, M = ca. 27 kDa) was expressed in E. coli and purified by His-tag-targeted affinity chromatography. For polymer-antibody coupling, 13 C-PMPC was carefully heated in vacuo at 105 ºC in the absence of any solvent to allow deprotection (retro-Diels Alder removal of the furan ring) of the terminal initiator moiety into an active maleimide form. Addition (Michael addition) of the terminal cysteine residue in scFv to the maleimide at a molar ratio of 13 C-PMPC/scFv = 24.5 afforded conjugate 13 C-PMPC-scFv with a mean molecular weight of 35,000 + 27,000 = 62,000, which was freed from 13 C-PMPC in excess on treatment with a His-tag column, purified by sizeexclusion chromatography (GPC) (Figure 1a Antigen Her2 is known to be highly expressed in gastric cancer as well as in breast cancer, but not in pancreatic cancer. 15 Thus, N87 (a human gastric cancer cell line) and SUIT2 (a human pancreatic cancer cell line) were used here as Her2(+) and Her2(-) tumor cells, respectively. 16 Model mice were obtained by transplanting the Her2(+) and Her2(-) tumor cells at the right shoulder and the contralateral left shoulder, respectively, of healthy mice (~20 g). Probe 13 C-PMPC-scFv (113.5 mg/kg = 1.83 μmol/kg body weight or 2.27 mg/20-g mouse) was intravenously injected into the tail vein of tumor-bearing mice. In vivo MR images of the mice were taken under probe-optimized double-resonance ( 1 H-{ 13 C}) conditions in essentially the same manner as described elsewhere 6c (Supplementary Information for details). Figure 2a shows a typical image (double-resonance image overlaid on a T2-weighted single-resonance ( 1 H) morphological image) 17 taken at 22 h after administration of the probe. We can clearly see that (1) the Her2(+) gastric tumor is clearly visualized while the Her2(-) pancreatic tumor is hardly visible, and (2) there is no appreciable accumulation of the probe in the liver, although some unidentified, noise-looking spots are still noticed. The observed Her2(+)/Her2(-) selectivity is probably a consequence of scFv-mediated active targeting of the Her2(+) tumor by the probe, since the reference probe 13 C-PMPC (Mn = 35,000), which lacks in the antibody scFv moiety, shows no notable affinity for the Her2(+) tumor (Figure 2b) . Figure 3 shows a rough time course of imaging of the tumor sites at 4 h, 22 h, and 46 h. The Her2(+) site exhibits a monotonous decrease in image intensity with signal-to-noise ratios of S/N = 12.9, 9.6, and 4.1 at 4 h, 22 h, and 46 h, respectively. The Her2(-) site is just barely imageable at 4 h, but then fades away in 1 day. Ex vivo measurements for the tumor sites removed from the probeadministered mouse clearly show selective accumulation of the probe in the Her2(+) tumor (Figure 1d ). Even at a time point of 48 h from injection, the double-resonance signal of the probe in Her2(+) is twice as intense as that in Her2(-). 18 The present active tumor-targeting may be compared with previously reported passive EPR tumor-targeting. There is a striking difference in the build-up/decay profiles. It takes ~2 days for the antibody-free probe 13 C-PMPC (Mn = 63,000) to settle in colon 26 tumor with a gradual increase in the S/N ratio, and the probe accumulated in the tumor is stably retained therein for at least a week without undergoing clearance. 6c In marked contrast, uptake of the antibody-functionalized probe 13 C-PMPC-scFv (Mn = 62,000) by the N87 tumor is rapid (<4 h), but the probe is cleared rather rapidly with a gradual decrease in the S/N ratio within ~2 days (Figure 3, top) . On the other hand, the two probes share a common characteristic. As in the case of 13 C-PMPC, 6c there is no appreciable nonspecific binding of probe 13 C-PMPC-scFv to normal organs, especially the liver (Figure 2a) , which is often a major deposition site of nano-probes and nanomedicines. 19 Formally, comparison of these two probes helps us to characterize the role of scFv. However, there is an obstacle. The two probes with similar molecular weights (62,000 vs 63,000) are far from analogous to each other with respect to size. Probe 13 C-PMPC, which is plausibly free from aggregation, forms compact particles with a mean dynamic light scattering (DLS) size of dDLS = 13.1 ± 0.13 nm for 13 C-PMPC63,000 as reported previously 6c or dDLS = 8.41 ± 0.05 nm for 13 C-PMPC35,000 (Figure 4b) . In marked contrast, the antibody-functionalized probe 13 C-PMPC-scFv62,000 is highly aggregated and forms large particles with dDLS = 175.3 ± 2.5 nm (Figure 4a ).
Size is an important factor that governs the pharmacokinetics of nano-particles. Roughly, EPR-relevant sizes are in the range of 10-100 nm. 20 Smaller (<10 nm) and larger (>100 nm) particles are susceptible to clearance, respectively, by renal excretion 21 and the reticuloendothelial systems, particularly via phagocytosis by macrophages distributed in various organs such as liver. 22 Another factor to consider is biocompatibility. Phosphorylcholine comprises the head group of cell-membrane lipids (phosphatidylcholine), and polymers derived therefrom, including PMPC, are known to be biologically inert. 23 They escape from phagocytosis, probably because they are not recognized as foreign bodies by macrophages. 24 In this context, the biocompatibility of PMPC may primarily deactivate the macrophage/liver pathway for PMPC-based polymers regardless of their sizes. The rapid clearance of 13 C-PMPC-scFv is more difficult to explain at present. The antibody fragment scFv conjugated with a long polymer chain (PMPC), possibly via electrostatic interaction between them, might be susceptible to hydrolytic degradation to lose its affinity for the Her2(+) N87 site, although this is by no means conclusive and further rigorous investigation will be required. In this work, we investigated how 13 C-PMPC performs as a self-traceable MR tag for a tumor-targeting antibody. The antibody-tag conjugate exhibited expected antigen(+)/antigen(-) selectivity and MR-imaged the antigen(+) tumor with a rapid build-up/decay or accumulation/clearance profile. The dose of the present probe (113.5 mg/kg = 1.83 μmol/kg) is comparable to (on a weight basis) or much lower (on a molar basis) than that of Magnevist (74 mg/kg = 0.1 mmol/kg), a clinical contrast agent that is widely used in current MRI. The detection limit of imaging of the present 13 C-PMPC-scFv probe would be ~18 μM, 25 which is slightly higher than the detection limit (several μM) reported for a gadolinium contrast agent. 26 The use of synthetic polymers as a tag may offer both advantages and disadvantages compared with small optical tags such as fluorophores. Synthetic polymers are also widely and uniquely used as carriers of drugs and genes 27 and as stabilizers of clinical protein and nucleic acid medications. 28 In this context, this work may represent a step toward the visualization of various delivery/localization events mediated by synthetic polymers. At the same time, this work revealed an unexpected problem: aggregation-free PMPC becomes highly aggregated upon modification with scFv, which (dDLS = 10.3 nm) alone supposedly does not aggregate. Phosphorylcholine polymer (PMPC) is zwitterionic, i.e., it is an ammonium-phosphate polybetaine. The scFv moiety seems to perturb the otherwise intramolecular/intrastrand electrostatic interaction of PMPC 29 and promote intermolecular/interstrand interaction thereof. Further work is now underway in our laboratories to gain deeper insight into the pharmacokinetics of the present and related PMPC probes and to shed more light on the effects of terminal substituents on the aggregation states of PMPC polymers.
